Theorem Clinical Research

AstraZeneca

Treasury’s tax inversion changes scuttle some big biopharma mergers, modify others, prompting calls for Congressional corporate tax reform

Thursday, October 23, 2014 03:50 PM

The widely-discussed $54.6 billion acquisition of Dublin-based Shire by AbbVie is officially canceled, having crumbled after a notice by the U.S. Treasury Department to tighten tax rules that deter U.S. companies from moving their legal headquarters to countries with lower business taxes.

More... »

Quest Diagnostics

ProNAi Therapeutics adds five to senior management team

Thursday, October 23, 2014 03:17 PM

ProNAi Therapeutics, a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform, has added five seasoned executives to its senior management team.

More... »


Inovio Pharmaceuticals, MedImmune, University of Pennsylvania partner

Wednesday, October 22, 2014 11:39 AM

The Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of PennsylvaniaInovio Pharmaceuticals and MedImmune, the global biologics R&D arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies (mAbs) for infectious disease treatment. DARPA is an agency of the U.S. Department of Defense that creates and supports novel technologies important for national security.

More... »

AstraZeneca, University of Cambridge strengthen partnership

Friday, October 17, 2014 12:46 PM

AstraZeneca, together with its global biologics R&D arm MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership. The latest collaborations reinforce AZ’s commitment to creating a permeable research infrastructure in Cambridge following its decision to locate one of its three global R&D centers and its global headquarters in the city, which has been home to MedImmune’s biologics research laboratories for 25 years.

More... »

Moderna, Karolinska Institute to collaborate on messenger RNA therapeutics

Thursday, October 16, 2014 02:30 PM

Moderna Therapeutics, a Cambridge, Mass.-based pharma, has formed a strategic, long-term collaboration with Karolinska Institute (KI) and Karolinska University Hospital (KUH), both in Sweden, for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics enable the in vivo production of both intracellular proteins and secreted proteins.

More... »

Inversion rule change prompts AbbVie to halt Shire takeover

Thursday, October 16, 2014 02:21 PM

In what could have been a major pharmaceutical acquisition and one of the biggest tax inversion deals, Chicago-based AbbVie has recommended its shareholders vote against its proposed $54 billion takeover of Shire, a Dublin-headquartered pharmaceutical company specializing in medications to treat attention deficit disorder and rare diseases

More... »

Exostar, BT partner

Thursday, October 16, 2014 07:00 AM

Exostar, a Herndon, Va.-based provider of secure, cloud-based solutions that improve collaboration, information sharing and supply chain management for communities of partners, has become a specialist member of the BT for Life Sciences partner ecosystem. Exostar’s secure identity and access management (IAM) and enterprise federation solutions now can be paired with BT’s Workbench Informatics solution for scientists.

More... »

PPD acquires X-Chem

Tuesday, October 7, 2014 10:30 AM

Pharmaceutical Product Development (PPD), a Wilmington, N.C.-based CRO, has exercised its option to acquire the remaining minority ownership interest of X-Chem. X-Chem, a biotechnology company based in Waltham, Mass., will continue to operate as a biotechnology company with its entire existing staff, including its management team led by CEO and founder Richard W. Wagner, Ph.D., along with executive management team members Diala Ezzeddine, Ph.D., chief business officer; Matthew Clark, Ph.D., sr. vice president of research; and Lee Babiss as chairman of the board.

More... »

Medimmune, Cancer Research U.K. establish laboratory for biologic cancer medicines

Friday, September 26, 2014 03:24 PM

MedImmune, AstraZeneca’s global biologics R&D arm, and Cancer Research U.K., with its commercial arm Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, U.K. The new laboratory will focus on the discovery and development of novel biologic cancer treatments over an initial five-year period.

More... »

Cancer Core Europe consortium launches

Friday, September 26, 2014 03:15 PM

Cancer Core Europe—a consortium to address the cancer care/research continuum challenge, has launched. Its members are Gustave Roussy Cancer Campus Grand Paris; Cambridge Cancer Center, based in the U.K.; Karolinska Institute, of Stockholm, Sweden; the Netherlands Cancer InstituteVall d'Hebron Institute of Oncology (VHIO), of Barcelona, Spain; and the German Cancer Research Center (DKFZ) and its National Center for Tumor Diseases (NCT).

More... »


CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs